Development of an Industrial Manufacturing Platform for Adeno-Associated Virus (AAV) production to support Regenerative Gene Therapy products

Adeno-associated virus (AAV) vectors—the microscopic delivery vehicles used in gene therapy—cannot currently be manufactured in large enough quantities to supply clinical trials. This matters because AAV vectors are the preferred method for delivering corrective genes to treat inherited and rare diseases, as well as conditions of the eye that are life-threatening or severely diminish quality of life. The bottleneck is not the science of the therapy itself, but the industrial process for making the vectors. Current manufacturing methods do not scale up reliably, which keeps many promising treatments stuck in the lab. The collaboration between Cobra and CPI aims to develop a scalable, flexible manufacturing platform for AAV production. If successful, this would allow more gene therapy products to enter clinical testing and, ultimately, reach patients. The practical impact would be felt in the pharmaceutical supply chain: a reliable, industrial-scale production process that can support a pipeline of new medicines for a range of currently intractable diseases. This is not fundamental science—it is applied process engineering with a direct route to patient benefit.